
    
      Between March 2015 and November 2015, 99 participants (59 naïve and 40 experienced) infected
      with HCV GT4 were enrolled in the study. Eligible participants received daily oral 400 mg SOF
      ( (Sovaldi, Gilead Sciences, Inc., USA), RBV (Copegus, Roche, Europe) based on body weight: <
      75 kg, 1000 mg; ≥75 kg, 1200 mg), the dose modified according to participants tolerability,
      plus 180 μg PegINFα-2 once weekly for 12 weeks.

      Experienced participants included participants with a prior relapse or a null response to
      PegINF/RBV therapy.
    
  